Cargando…
Hypoxia-activated prodrugs and redox-responsive nanocarriers
Hypoxia is one of the marked features of malignant tumors, which is associated with several adaptation changes in the microenvironment of tumor cells. Therefore, targeting tumor hypoxia is a research hotspot for cancer therapy. In this review, we summarize the developing chemotherapeutic drugs for t...
Autores principales: | Zeng, Yun, Ma, Jingwen, Zhan, Yonghua, Xu, Xinyi, Zeng, Qi, Liang, Jimin, Chen, Xueli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202002/ https://www.ncbi.nlm.nih.gov/pubmed/30425475 http://dx.doi.org/10.2147/IJN.S173431 |
Ejemplares similares
-
Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
por: Ma, Weina, et al.
Publicado: (2020) -
Health effects of kiwi wine on rats: an untargeted metabolic fingerprint study based on GC-MS/TOF
por: Zeng, Qi, et al.
Publicado: (2019) -
Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly
por: Fu, Q., et al.
Publicado: (2015) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021) -
In Vivo Dual-Modality Fluorescence and Magnetic Resonance Imaging-Guided Lymph Node Mapping with Good Biocompatibility Manganese Oxide Nanoparticles
por: Zhan, Yonghua, et al.
Publicado: (2017)